Monographie - Tigecycline

Última actualização :
19/11/2024

Tigecycline

estrutura química

Nomes comerciais nos diversos países

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Eticina	México
Grexyl	México
Linicetil	México
Mrsacin	Turquia
Tecygen	Chilli
Tigecid	Turquia
Tigecilina	Argentina, Chilli, Equator
Tigecycline	Canadá
Tigetop	Chilli
Tizoxim	Argentina
Tygacil	Alemanha, Arábia Saudita, Argentina, Austria, Bélgica, Canadá, Chilli, Colômbia, Dinamarca, Emirados Árabes Unidos, Equator, Espanha, Estados Unidos de América, Finlandia, França, Gran-bretanha, Grècia, Hungria, Irlanda, Islandia, Itália, Japón, Luxemburgo, Malásia, México, Noruega, nova Zelândia, Países Baixos, Peru, Polonia, Portugal, Romènia, Suècia, Suicia, Turquia, Venezuela
Zomiprerin	Peru

Bibliografía : Tigecycline

	tipo	publicação
2262	jornal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratório	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	jornal	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratório	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratório	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratório	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratório	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	jornal	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	jornal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	jornal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	jornal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	jornal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales